The main purpose of this study is to investigate whether long-term oral administration of Staphylococcus albicans tablets can significantly reduce the number of acute exacerbations in patients with bronchiectasis. Secondary objective is to explore whether long-term oral administration of Staphylococcus albicans tablets can reduce the risk of hospitalization in patients with bronchiectasis and whether it can improve the quality of life of patients. Other purpose is to explore the regulatory effect of long-term oral administration of Staphylococcus albicans tablets on the immune function of patients with bronchiectasis.
Patients with bronchiectasis diagnosed by clinical manifestations and chest HRCT according to the diagnostic criteria for bronchiectasis;
Patients with idiopathic or post-infectious bronchiectasis;
18years old;
Patients should have at least 2 acute exacerbations within 1 year before enrollment;
Cystic fibrosis;
Immunodeficiency, allergic bronchopulmonary aspergillosis, etc.;
Traction bronchiectasis caused by severe emphysema or advanced pulmonary fibrosis;
Still smoking;